I-Wei Lin

I-Wei Lin

Auto-generated profile, based on publicly available information

I-Wei Lin

Division of Hematology and Oncology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei City, Taiwan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Case Reports in Hematology
Verified
Journal Article
Open access
ILI-Wei Lin
I-Wei Lin
Ken-Hong LimKen-Hong Lim
Ken-Hong Lim
YHYen-Chang Huang
Yen-Chang Huang
MSMeng-Ta Sung
Meng-Ta Sung
Immune thrombocytopenia purpura (ITP) is initially treated with steroids, but TPO‐RAs such as eltrombopag are used for chronic cases. Though effective, eltrombopag has been linked to thromboembolic events, with cerebral venous thrombosis (CVT) being a rare complication. A 20‐year‐old woman with ITP developed severe headaches, nausea, and vomiting five days after starting eltrombopag. CT scans revealed a dense clot in the right transverse sinus, indicating CVT. Lab data showed elevated platelet counts and D‐dimer levels. MRV confirmed CVT, leading to the discontinuation of eltrombopag and initiation of anticoagulant therapy. Recurring thrombocytopenia necessitated further treatment adjustments, including rituximab and cyclosporine, resulting in improved platelet counts and CVT resolution. This case highlighted that CVT is a serious but rare side effect of eltrombopag in ITP patients. Early detection, prompt anticoagulation, and cautious TPO‐RA management are crucial for preventing thromboembolic events.